4,521 Shares in Danaher Corporation $DHR Acquired by First National Bank Sioux Falls

Key Points

• First National Bank Sioux Falls acquired 4,521 shares of Danaher Corporation (NYSE:DHR) valued at approximately $893,000 in the second quarter.
• Wall Street analysts have a predominantly positive outlook on Danaher, with an average target price of $246.35 and 17 out of 20 analysts rating it as a "Buy."
• Danaher announced a quarterly dividend of $0.32 per share, with the ex-dividend date set for September 26, reflecting a dividend yield of 0.7%.

First National Bank Sioux Falls acquired a new stake in shares of Danaher Corporation (NYSE:DHR - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 4,521 shares of the conglomerate's stock, valued at approximately $893,000.

Several other hedge funds also recently bought and sold shares of the company. AG2R LA Mondiale Gestion D Actifs purchased a new position in Danaher during the first quarter valued at approximately $4,598,000. Voya Investment Management LLC grew its stake in Danaher by 1.1% in the 1st quarter. Voya Investment Management LLC now owns 886,002 shares of the conglomerate's stock worth $181,630,000 after buying an additional 9,926 shares in the last quarter. Howe & Rusling Inc. grew its stake in Danaher by 103.7% in the 1st quarter. Howe & Rusling Inc. now owns 31,226 shares of the conglomerate's stock worth $6,401,000 after buying an additional 15,897 shares in the last quarter. Guinness Asset Management LTD grew its stake in Danaher by 5.3% in the 1st quarter. Guinness Asset Management LTD now owns 171,960 shares of the conglomerate's stock worth $35,253,000 after buying an additional 8,624 shares in the last quarter. Finally, eCIO Inc. purchased a new position in Danaher in the 1st quarter worth approximately $131,000. Hedge funds and other institutional investors own 79.05% of the company's stock.

Danaher Stock Up 0.8%

DHR stock traded up $1.52 during trading on Thursday, hitting $194.46. 1,417,635 shares of the stock traded hands, compared to its average volume of 4,133,126. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The stock has a market cap of $139.24 billion, a price-to-earnings ratio of 41.40, a price-to-earnings-growth ratio of 2.66 and a beta of 0.75. The firm's 50 day moving average is $200.61 and its two-hundred day moving average is $198.55. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm had revenue of $5.94 billion for the quarter, compared to analysts' expectations of $5.83 billion. During the same quarter in the prior year, the business earned $1.72 EPS. The business's quarterly revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, sell-side analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Friday, September 26th. Danaher's dividend payout ratio (DPR) is 27.23%.

Insider Transactions at Danaher

In other Danaher news, Director Teri List sold 2,778 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares of the company's stock, valued at $4,379,706.06. This trade represents a 11.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 11.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

DHR has been the subject of a number of recent research reports. Evercore ISI lowered their price objective on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Robert W. Baird boosted their price objective on shares of Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a report on Friday, July 18th. Wall Street Zen upgraded shares of Danaher from a "hold" rating to a "buy" rating in a report on Friday, June 27th. Royal Bank Of Canada set a $241.00 price target on shares of Danaher in a report on Tuesday, September 2nd. Finally, Barclays reiterated an "overweight" rating and set a $225.00 price target (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Seventeen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, Danaher presently has a consensus rating of "Moderate Buy" and an average price target of $246.35.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.